

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 6, 2002

BECTON, DICKINSON AND COMPANY

(Exact name of registrant as specified in its charter)

<TABLE>		
<S>	<C>	<C>
New Jersey	001-4802	22-0760120
----- (State or other juris- diction of incorporation)	----- (Commission File Number)	----- (IRS Employer Iden- tification Number)
1 Becton Drive, Franklin Lakes, New Jersey		07417-1880
----- (Address of principal executive offices)		----- (Zip Code)

Registrant's telephone number, including area code (201) 847-6800

N/A

(Former name or former addresses if changed since last report.)

Item 5. OTHER EVENTS

On November 6, 2002 the Registrant announced in a press release its results for the fourth quarter and fiscal year ended September 30, 2002.

A copy of the press release is attached as Exhibit 99.1.

Item 7. Financial Statements. Pro Forma Financial Information and Exhibits.

(c) Exhibits.

Exhibit 99.1 Press release dated November 6, 2002
announcing the financial results for the fourth quarter and
fiscal year ended September 30, 2002.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Gary DeFazio

Date: November 6, 2002

INDEX TO EXHIBITS

<TABLE>
<CAPTION>

Exhibit Number -----	Description of Exhibits -----
<S> 99.1	<C> Press release issued November 6, 2002

</TABLE>

STATEMENT OF DIFFERENCES

The trademark symbol shall be expressed as.....'TM'

Contact:

Dean J. Paranicas/Investor Relations - 201-847-7102
Charles A. Borgognoni/Corporate Communications - 201-847-6651

BD ANNOUNCES RECORD FISCAL FOURTH QUARTER
AND FULL YEAR REVENUES

Franklin Lakes, NJ (November 6, 2002) - BD (Becton, Dickinson and Company) (NYSE: BDX) today reported record quarterly revenues of \$1.077 billion for the fiscal fourth quarter ended September 30, 2002, an increase of 9 percent from the same period a year ago. For the full year, the Company reported record revenues of \$4.033 billion, an 8 percent increase over a year ago.

Diluted earnings per share were 50 cents for the fourth quarter, which included a charge of \$13 million before taxes (recorded in "Other Expense") reflecting the non-cash write-down of two equity investments resulting from a decline in market values. Excluding the charge, diluted earnings per share would have been 53 cents. Diluted earnings per share for the full year of \$1.79 also included special charges recorded in the second and third quarters totaling 6 cents per share, relating to the previously-announced manufacturing restructuring in the BD Medical Systems segment.

Results for fiscal 2002 also reflected a 10 cent benefit from the adoption of Statement of Financial Accounting Standards No. 142, "Goodwill and Other Intangible Assets." Fiscal 2001 diluted earnings per share were 49 cents for the fourth quarter and \$1.49 for the full year, which included a charge in the amount of 14 cents per share for the cumulative effect of an accounting change recorded in connection with the Company's adoption of the Securities and Exchange Commission's Staff Accounting Bulletin No. 101, "Revenue Recognition in Financial Statements."

"Our strategies aimed at accelerating top line growth and driving productivity are working. Revenue and earnings growth represent the achievement of the full year performance objectives we had communicated to our shareholders at the beginning of the year," said Edward J. Ludwig, Chairman, President and Chief Executive Officer. "These results reflect solid revenue performance from all three business segments, and in particular from our growth drivers. Safety-engineered product sales grew 38 percent to \$573 million, prefillable drug delivery devices enjoyed a year of mid-teens growth, and BD Biosciences closed the year strongly. Our strong cash flow continues to be driven by our ongoing efforts to achieve greater operational effectiveness and even stronger balance sheet productivity."

Segment Results

In the BD Medical Systems segment, worldwide revenues of \$574 million increased 7 percent for the quarter. Included in these revenues were U.S. safety-engineered product sales of \$103 million, versus \$78 million in the prior year's quarter. Sales of safety-engineered products for the full year totaled \$353 million, versus \$253 million in the prior year. Also contributing to the growth of the segment were sales of prefillable drug delivery devices, which grew 9 percent in the quarter and 17 percent for the full year. The overall growth rate in the segment was partly offset by reduced sales of certain conventional devices in the U.S. due to the transition to safety-engineered devices.

In the BD Clinical Laboratory Solutions segment, worldwide revenues increased 11 percent for the quarter to \$326 million. Revenue growth of 10 percent in the Preanalytical Solutions portion of the segment was due to U.S. safety-engineered product sales, which were \$64 million, versus \$50 million in the prior year's quarter. Sales of safety-engineered products for the full year totaled \$220 million, versus \$163 million in the prior year. The overall growth rate of the Preanalytical Solutions portion of the segment was partly offset by reduced sales of certain conventional devices in the U.S. due to the transition to safety-engineered devices. Also contributing to the segment's performance were worldwide sales of the Diagnostic Systems portion of the segment, which

increased by 11 percent, driven by strong worldwide performance of its molecular diagnostic platform, BD ProbeTec ET™.

In the BD Biosciences segment, worldwide revenues grew 14 percent to \$177 million for the quarter. Revenue growth was driven by strong sales of flow cytometry instruments and reagents (Immunocytometry Systems), immunology/cell biology reagents (Pharmingen), and Discovery Labware products. Molecular biology reagent (Clontech) revenues of \$18 million decreased by approximately \$2 million versus the prior year's quarter due to continued weakness in some portions of the molecular biology market, largely due to softness in pharmaceutical/biotech research and development spending, and a shift in pharmaceutical focus from early stage drug target identification to later stage drug development. BD Biosciences has refocused the Clontech research and development efforts toward producing a product portfolio aligned with changing customer focus, and has streamlined operations.

Geographic Results

On a geographic basis, fourth quarter revenues in the U.S. increased 8 percent to \$590 million. Revenues outside the U.S. of \$487 million grew 10 percent, or 7 percent at constant foreign exchange rates. For the full year, revenues in the U.S. increased 8 percent to \$2.173 billion. Revenues of \$1.860 billion outside the U.S. increased by 8 percent, or 9 percent at constant foreign exchange rates.

Fiscal 2003 Outlook

The Company confirmed its estimate of approximately \$2.07 for diluted earnings per share in fiscal 2003. The Company also indicated that it estimates first quarter diluted earnings per share would approximate 39 cents. Included in first quarter estimated diluted earnings per share are

approximately 2 cents of incremental costs associated with the anticipated U.S. launch of the Company's blood glucose monitoring product.

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products.

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding the Company's performance, including future revenues, products and income, or events or developments that the Company expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of the Company and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; uncertainties of litigation; the Company's ability to achieve sales and earnings forecasts, which are based on sales volume and product mix assumptions, to achieve its cost savings objectives, and to achieve anticipated synergies and other cost savings in connection with acquisitions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in the Company's ability to maintain favorable supplier arrangements and relationships; changes in interest or foreign currency exchange rates; delays in product introductions; and changes in health care or other governmental regulation, as well as other factors discussed in this press release and in the Company's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements.

BD's news releases can be found on its website at www.bd.com or through Business Wire at www.businesswire.com. A conference call with analysts regarding this news release will be broadcast live on BD's website at 8:30 a.m. EST Thursday, November 7, 2002. The conference call will be available for playback on BD's website or at 1-888-562-0218 (domestic) and 1-402-998-1407 (international) through the close of business on November 14, 2002.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>
<CAPTION>

	Three Months Ended September 30,		
	2002	2001	% Change
<S>	<C>	<C>	<C>
REVENUES	\$1,076,692	\$987,525	9.0
Cost of products sold	546,703	497,745	9.8
Selling and administrative	282,232	257,383	9.7
Research and development	55,598	51,505	7.9
TOTAL OPERATING COSTS AND EXPENSES	884,533	806,633	9.7
OPERATING INCOME	192,159	180,892	6.2
Interest expense, net	(6,216)	(7,697)	(19.2)
Other (expense) income, net	(13,959)	30	NM
INCOME BEFORE INCOME TAXES	171,984	173,225	(0.7)
Income tax provision	40,588	40,815	(0.6)
NET INCOME	\$ 131,396	\$132,410	(0.8)
EARNINGS PER SHARE			
Basic	\$ 0.51	\$ 0.51	-
Diluted	\$ 0.50	\$ 0.49	2.0
AVERAGE SHARES OUTSTANDING			
Basic	256,376	258,952	
Diluted	264,091	270,376	

</TABLE>

NM - Not Meaningful

See Note to Consolidated Income Statements.

Page 1

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>
<CAPTION>

	Twelve Months Ended September 30,		
	2002	2001	% Change
<S>	<C>	<C>	<C>
REVENUES	\$4,033,069	\$3,746,182	7.7
Cost of products sold	2,083,669	1,913,292	8.9
Selling and administrative	1,032,043	983,296	5.0
Research and development	220,186	211,834	3.9
Special charges	21,508	-	NM
TOTAL OPERATING COSTS AND EXPENSES	3,357,406	3,108,422	8.0
OPERATING INCOME	675,663	637,760	5.9
Interest expense, net	(33,304)	(55,414)	(39.9)
Other expense, net	(13,770)	(5,596)	NM
INCOME BEFORE INCOME TAXES	628,589	576,750	9.0
Income tax provision	148,607	138,348	7.4
INCOME BEFORE CUMULATIVE EFFECT OF CHANGE IN ACCOUNTING PRINCIPLE, NET OF TAX	479,982	438,402	9.5
Cumulative effect, net of tax	-	(36,750)	NM

NET INCOME	\$ 479,982	\$ 401,652	19.5

BASIC EARNINGS PER SHARE			
Before Cumulative Effect	\$ 1.85	\$ 1.69	9.5
Cumulative Effect	-	(0.14)	NM

Basic Earnings Per Share	\$ 1.85	\$ 1.55	NM

DILUTED EARNINGS PER SHARE			
Before Cumulative Effect	\$ 1.79	\$ 1.63	9.8
Cumulative Effect	-	(0.14)	NM

Diluted Earnings Per Share	\$ 1.79	\$ 1.49	NM

AVERAGE SHARES OUTSTANDING			
Basic	258,016	257,128	
Diluted	268,183	268,833	

</TABLE>

NM - Not Meaningful

See Note to Consolidated Income Statements.

Page 2

BECTON DICKINSON AND COMPANY
NOTE TO CONSOLIDATED INCOME STATEMENTS
Twelve Months Ended September 30, 2002

Fiscal 2002 revenues included hedging costs of approximately \$3.6 million for the fourth quarter and \$10.6 million for the twelve months, compared with \$1.3 million and \$9.9 million, respectively, in fiscal 2001. These costs related to BD's purchased option contracts to hedge a portion of its anticipated sales from the United States to non-U.S. customers. Hedging costs of approximately \$8.1 million for the first six months of fiscal 2001 were recorded in Other Expense under previous accounting guidance. This amount has been reclassified to revenues. Also included in revenues were losses on forward contracts of approximately \$0.9 million for the fourth quarter and net gains on purchased option and forward contracts of approximately \$3.5 million for the twelve months, compared with gains of \$4.2 million and \$12.4 million, respectively, in fiscal 2001.

Page 3

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

<TABLE>

<CAPTION>

	Three Months Ended September 30,		
	2002	2001	% Change
<S>	<C>	<C>	<C>
MEDICAL SYSTEMS			
United States	\$ 300,433	\$ 281,652	6.7
International	273,351	255,643	6.9

TOTAL	\$ 573,784	\$ 537,295	6.8

CLINICAL LABORATORY SOLUTIONS			
United States	\$ 194,747	\$ 175,719	10.8
International	131,136	119,306	9.9

TOTAL	\$ 325,883	\$ 295,025	10.5

BIOSCIENCES			
United States	\$ 94,574	\$ 87,878	7.6
International	82,451	67,327	22.5

TOTAL	\$ 177,025	\$ 155,205	14.1

TOTAL REVENUES			

United States	\$ 589,754	\$ 545,249	8.2
International	486,938	442,276	10.1
TOTAL	\$1,076,692	\$ 987,525	9.0

<CAPTION>

	Twelve Months Ended September 30,		
	2002	2001	% Change
<S>	<C>	<C>	<C>
MEDICAL SYSTEMS			
United States	\$1,092,428	\$1,007,601	8.4
International	1,058,946	997,025	6.2
TOTAL	\$2,151,374	\$2,004,626	7.3
CLINICAL LABORATORY SOLUTIONS			
United States	\$ 735,613	\$ 679,880	8.2
International	500,706	471,637	6.2
TOTAL	\$1,236,319	\$1,151,517	7.4
BIOSCIENCES			
United States	\$ 344,853	\$ 329,042	4.8
International	300,523	260,997	15.1
TOTAL	\$ 645,376	\$ 590,039	9.4
TOTAL REVENUES			
United States	\$2,172,894	\$2,016,523	7.8
International	1,860,175	1,729,659	7.5
TOTAL	\$4,033,069	\$3,746,182	7.7

</TABLE>

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
Three Months Ended September 30,
(Unaudited; Amounts in thousands)

<TABLE>

<CAPTION>

	United States		
	2002	2001	% Change
<S>	<C>	<C>	<C>
MEDICAL SYSTEMS			
Medical Surgical	\$199,340	\$178,590	11.6
Consumer Health Care	75,295	77,349	(2.7)
Pharmaceutical Systems	20,295	19,142	6.0
Ophthalmic Systems	5,503	6,571	(16.3)
TOTAL	\$300,433	\$281,652	6.7
CLINICAL LABORATORY SOLUTIONS			
Preanalytical Solutions	\$106,364	\$ 95,734	11.1
Diagnostic Systems	88,383	79,985	10.5
TOTAL	\$194,747	\$175,719	10.8
BIOSCIENCES			
Discovery Labware	27,050	22,859	18.3
Immunocytometry & Reagents:			
Flow Cytometry Instruments & Reagents	36,249	33,584	7.9
Molecular Biology Reagents	12,960	15,298	(15.3)
Immunology/Cell Biology Reagents	18,315	16,137	13.5
Total Immunocytometry & Reagents	67,524	65,019	3.9
TOTAL	\$ 94,574	\$ 87,878	7.6

TOTAL UNITED STATES	\$589,754	\$545,249	8.2
---------------------	-----------	-----------	-----

<CAPTION>

	International		
	2002	2001	% Change
<S>	<C>	<C>	<C>
MEDICAL SYSTEMS			
Medical Surgical	\$153,184	\$146,435	4.6
Consumer Health Care	48,236	44,804	7.7
Pharmaceutical Systems	64,448	58,300	10.5
Ophthalmic Systems	7,483	6,104	22.6
TOTAL	\$273,351	\$255,643	6.9
CLINICAL LABORATORY SOLUTIONS			
Preanalytical Solutions	\$ 64,910	\$ 60,355	7.5
Diagnostic Systems	66,226	58,951	12.3
TOTAL	\$131,136	\$119,306	9.9
BIOSCIENCES			
Discovery Labware	18,662	16,339	14.2
Immunocytometry & Reagents:			
Flow Cytometry Instruments & Reagents	46,787	37,752	23.9
Molecular Biology Reagents	5,083	4,382	16.0
Immunology/Cell Biology Reagents	11,919	8,854	34.6
Total Immunocytometry & Reagents	63,789	50,988	25.1
TOTAL	\$ 82,451	\$ 67,327	22.5
TOTAL INTERNATIONAL	\$486,938	\$442,276	10.1

</TABLE>

Page 5

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION
 REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
 Three Months Ended September 30, (continued)
 (Unaudited; Amounts in thousands)

<TABLE>
 <CAPTION>

	Total		
	2002	2001	% Change
<S>	<C>	<C>	<C>
MEDICAL SYSTEMS			
Medical Surgical	\$ 352,524	\$ 325,025	8.5
Consumer Health Care	123,531	122,153	1.1
Pharmaceutical Systems	84,743	77,442	9.4
Ophthalmic Systems	12,986	12,675	2.5
TOTAL	\$ 573,784	\$ 537,295	6.8
CLINICAL LABORATORY SOLUTIONS			
Preanalytical Solutions	\$ 171,274	\$ 156,089	9.7
Diagnostic Systems	154,609	138,936	11.3
TOTAL	\$ 325,883	\$ 295,025	10.5
BIOSCIENCES			
Discovery Labware	45,712	39,198	16.6
Immunocytometry & Reagents:			
Flow Cytometry Instruments & Reagents	83,036	71,336	16.4
Molecular Biology Reagents	18,043	19,680	(8.3)
Immunology/Cell Biology Reagents	30,234	24,991	21.0
Total Immunocytometry & Reagents	131,313	116,007	13.2
TOTAL	\$ 177,025	\$ 155,205	14.1

TOTAL REVENUES	\$1,076,692	\$ 987,525	9.0
----------------	-------------	------------	-----

</TABLE>

<TABLE>
<CAPTION>

	FX Neutral % Growth	
	International	Total
<S>	<C>	<C>
MEDICAL SYSTEMS		
Medical Surgical	3.5	8.0
Consumer Health Care	5.5	0.3
Pharmaceutical Systems	2.1	3.1
Ophthalmic Systems	17.5	-
TOTAL	3.9	5.3
CLINICAL LABORATORY SOLUTIONS		
Preanalytical Solutions	3.3	8.1
Diagnostic Systems	9.8	10.2
TOTAL	6.5	9.1
BIOSCIENCES		
Discovery Labware	11.3	15.4
Immunocytometry & Reagents:		
Flow Cytometry Instruments & Reagents	19.8	14.2
Molecular Biology Reagents	6.9	(10.3)
Immunology/Cell Biology Reagents	25.9	17.9
Total Immunocytometry & Reagents	19.8	10.8
TOTAL	17.7	12.0
TOTAL	6.7	7.5

</TABLE>

Page 6

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
Twelve Months Ended September 30,
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	United States		
	2002	2001	% Change
<S>	<C>	<C>	<C>
MEDICAL SYSTEMS			
Medical Surgical	\$ 720,593	\$ 630,666	14.3
Consumer Health Care	275,643	291,371	(5.4)
Pharmaceutical Systems	71,122	57,606	23.5
Ophthalmic Systems	25,070	27,958	(10.3)
TOTAL	\$1,092,428	\$1,007,601	8.4
CLINICAL LABORATORY SOLUTIONS			
Preanalytical Solutions	\$ 383,482	\$ 345,699	10.9
Diagnostic Systems	352,131	334,181	5.4
TOTAL	\$ 735,613	\$ 679,880	8.2
BIOSCIENCES			
Discovery Labware	99,595	89,828	10.9
Immunocytometry & Reagents:			
Flow Cytometry Instruments & Reagents	124,327	119,929	3.7
Molecular Biology Reagents	54,203	60,707	(10.7)
Immunology/Cell Biology Reagents	66,728	58,578	13.9

Total Immunocytometry & Reagents	245,258	239,214	2.5
TOTAL	\$ 344,853	\$ 329,042	4.8
TOTAL UNITED STATES	\$2,172,894	\$2,016,523	7.8

<CAPTION>

	International		
	2002	2001	% Change
<S>	<C>	<C>	<C>
MEDICAL SYSTEMS			
Medical Surgical	\$ 591,782	\$ 567,845	4.2
Consumer Health Care	185,036	185,511	(0.3)
Pharmaceutical Systems	255,224	220,703	15.6
Ophthalmic Systems	26,904	22,966	17.1
TOTAL	\$1,058,946	\$ 997,025	6.2
CLINICAL LABORATORY SOLUTIONS			
Preanalytical Solutions	\$ 253,712	\$ 238,578	6.3
Diagnostic Systems	246,994	233,059	6.0
TOTAL	\$ 500,706	\$ 471,637	6.2
BIOSCIENCES			
Discovery Labware	68,228	61,463	11.0
Immunocytometry & Reagents:			
Flow Cytometry Instruments & Reagents	170,391	145,436	17.2
Molecular Biology Reagents	18,507	17,900	3.4
Immunology/Cell Biology Reagents	43,397	36,198	19.9
Total Immunocytometry & Reagents	232,295	199,534	16.4
TOTAL	\$ 300,523	\$ 260,997	15.1
TOTAL INTERNATIONAL	\$1,860,175	\$1,729,659	7.5

</TABLE>

Page 7

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

<TABLE>

<CAPTION>

	Total		
	2002	2001	% Change
<S>	<C>	<C>	<C>
MEDICAL SYSTEMS			
Medical Surgical	\$1,312,375	\$1,198,511	9.5
Consumer Health Care	460,679	476,882	(3.4)
Pharmaceutical Systems	326,346	278,309	17.3
Ophthalmic Systems	51,974	50,924	2.1
TOTAL	\$2,151,374	\$2,004,626	7.3
CLINICAL LABORATORY SOLUTIONS			
Preanalytical Solutions	\$ 637,194	\$ 584,277	9.1
Diagnostic Systems	599,125	567,240	5.6
TOTAL	\$1,236,319	\$1,151,517	7.4
BIOSCIENCES			
Discovery Labware	167,823	151,291	10.9
Immunocytometry & Reagents:			
Flow Cytometry Instruments & Reagents	294,718	265,365	11.1
Molecular Biology Reagents	72,710	78,607	(7.5)

Immunology/Cell Biology Reagents	110,125	94,776	16.2
Total Immunocytometry & Reagents	477,553	438,748	8.8
TOTAL	\$ 645,376	\$ 590,039	9.4
TOTAL REVENUES	\$4,033,069	\$3,746,182	7.7

</TABLE>

<TABLE>
<CAPTION>

	FX Neutral % Growth	
	International	Total
<S>	<C>	<C>
MEDICAL SYSTEMS		
Medical Surgical	6.3	10.5
Consumer Health Care	1.1	(2.9)
Pharmaceutical Systems	14.2	16.1
Ophthalmic Systems	17.5	2.2
TOTAL	7.3	7.9
CLINICAL LABORATORY SOLUTIONS		
Preanalytical Solutions	6.6	9.2
Diagnostic Systems	7.9	6.4
TOTAL	7.3	7.8
BIOSCIENCES		
Discovery Labware	13.4	11.9
Immunocytometry & Reagents:		
Flow Cytometry Instruments & Reagents	18.3	11.7
Molecular Biology Reagents	1.1	(8.0)
Immunology/Cell Biology Reagents	19.2	15.9
Total Immunocytometry & Reagents	17.0	9.1
TOTAL	16.1	9.8
TOTAL	8.6	8.2

</TABLE>